Corcept Therapeutics on February 19th had a trading volume of $379 million, an increase of 1075.74% compared to the previous trading day.

K-LinePoet · 2026-02-23T05:39:50+00:00

Corcept Therapeutics (CORT) traded with a volume of $379 million on February 19, 2026, a surge of 1075.74% from the previous day, but the stock price fell by 14.01%. The stock has decreased by a total of 53.43% over the past 52 weeks. The 2025 financial report shows that the company's revenue increased year-over-year, but net profit declined.

K-LinePoet

2026-02-23 05:39:50

Abstract generation in progress

On February 19, 2026, Corcept Therapeutics (CORT) had a trading volume of $379 million, ranking 307th among U.S. stocks for the day, with a 1075.74% increase compared to yesterday. The trading volume was 11.7068 million shares.

Corcept Therapeutics (CORT) declined 14.01% on February 19, 2026, closing at $34.24. The stock has fallen 10.69% over the past five trading days, down 14.12% for the entire month of February, down 1.61% year-to-date, and down 53.43% over the past 52 weeks.

*If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to the present (this also applies to companies listed for less than 1 month or fewer than 5 trading days).

Corcept Therapeutics (CORT)	Trading Volume / USD	Change in Trading Volume from Yesterday	Shares Traded
February 19, 2026	$379 million	1075.74%	11.7068 million
February 18, 2026	$32.2655 million	-3.39%	808,000
February 17, 2026	$33.396 million	22.10%	840,200
February 13, 2026	$27.3516 million	-48.54%	684,500
February 12, 2026	$53.1501 million	54.28%	1,368,000

Corcept Therapeutics released its third quarter 2025 financial report (cumulative) on November 4, 2025. From January 1, 2025, to September 30, 2025, revenue was $559 million, a 13.41% increase year-over-year, with a net profit of $75.364 million, down 31.77% year-over-year.

Corcept Therapeutics Incorporated was registered in Delaware on May 13, 1998. The company is a commercial-stage enterprise engaged in discovering and developing drugs that modulate cortisol hormone activity to treat severe endocrine, tumor, metabolic, and neurological diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.